$1.11 EPS Expected for Edwards Lifesciences Corporation (EW)

April 18, 2018 - By Marie Mckinney

Edwards Lifesciences Corporation (NYSE:EW) Logo

Analysts expect Edwards Lifesciences Corporation (NYSE:EW) to report $1.11 EPS on April, 24 after the close.They anticipate $0.17 EPS change or 18.09 % from last quarter’s $0.94 EPS. EW’s profit would be $233.68M giving it 31.56 P/E if the $1.11 EPS is correct. After having $0.94 EPS previously, Edwards Lifesciences Corporation’s analysts see 18.09 % EPS growth. The stock increased 0.65% or $0.91 during the last trading session, reaching $140.12. About 608,253 shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 44.06% since April 18, 2017 and is uptrending. It has outperformed by 32.51% the S&P500.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Coverage

Among 15 analysts covering Edwards Lifesciences (NYSE:EW), 12 have Buy rating, 0 Sell and 3 Hold. Therefore 80% are positive. Edwards Lifesciences had 29 analyst reports since October 25, 2017 according to SRatingsIntel. The company was maintained on Tuesday, April 10 by SunTrust. The rating was maintained by BMO Capital Markets with “Buy” on Thursday, December 7. Jefferies maintained Edwards Lifesciences Corporation (NYSE:EW) rating on Thursday, December 7. Jefferies has “Buy” rating and $136.0 target. Barclays Capital maintained it with “Overweight” rating and $155 target in Friday, February 2 report. The company was downgraded on Tuesday, January 2 by JP Morgan. The stock of Edwards Lifesciences Corporation (NYSE:EW) earned “Buy” rating by Canaccord Genuity on Thursday, February 1. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Buy” rating given on Thursday, January 4 by Barclays Capital. The firm has “Buy” rating given on Thursday, February 1 by Cowen & Co. The company was maintained on Sunday, November 5 by RBC Capital Markets. SunTrust maintained the stock with “Buy” rating in Wednesday, January 31 report.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company has market cap of $29.50 billion. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. It has a 51.9 P/E ratio. The firm also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patient??s diseased or defective heart valve.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.